氟替美维对老年慢性阻塞性肺疾病患者急性加重及死亡风险的影响

Effect of Flutemeivir on Acute Exacerbation and Mortality Risk in Elderly Patients with Chronic Obstructive Pulmonary Disease

目的分析氟替美维对老年慢性阻塞性肺疾病(COPD)患者急性加重及死亡风险的影响。方法选取2021年1月—2022年6月在苏州大学附属张家港医院就诊的老年COPD患者83例为研究对象。根据治疗方案将患者分为氟替美维治疗组(52例)和常规治疗组(31例)。所有患者进行适当的锻炼、戒烟和接受营养指导,在此基础上,氟替美维治疗组患者接受氟替美维吸入粉雾剂治疗,常规治疗组患者接受标准COPD治疗,两组均治疗4周。收集患者的临床资料,采用多元线性回归分析探讨老年COPD患者急性加重次数的影响因素;采用Kaplan-Meier法绘制生存曲线,生存曲线间的比较采用Log-rank检验。结果氟替美维治疗组冠心病发生率、急性加重次数低于常规治疗组(P<0.05)。多元线性回归分析结果显示,年龄、第1秒用力呼气容积占预计值百分比(FEV_(1)%)、动脉血二氧化碳分压(PaCO_(2))、慢性阻塞性肺疾病评估测试(CAT)评分、治疗方法是老年COPD患者急性加重次数的影响因素(P<0.05)。两组累积全因死亡率比较,差异无统计学意义(P>0.05)。结论氟替美维可有效降低老年COPD患者急性加重次数,但其可能不会降低患者的死亡风险。

Objective To analyze the effect of flutemeivir on acute exacerbation and mortality risk in elderly patients with chronic obstructive pulmonary disease(COPD).Methods A total of 83 elderly patients with COPD who were treated in Zhangjiagang Hospital Affiliated to Soochow University from January 2021 to June 2022 were selected as the study objects.According to the treatment plan,the patients were divided into flutemeivir treatment group(52 cases)and conventional treatment group(31 cases).All patients received appropriate exercise,smoking cessation,and nutritional guidance.Based on this,the patients in the flutemeivir treatment group received flutemeivir inhalation powder treatment,while the patients in the conventional treatment group received standard COPD treatment.Both groups were treated for 4 weeks.The clinical data of patients were collected.Multiple linear regression analysis was used to investigate the influencing factors of the number of acute exacerbation in elderly COPD patients.Kaplan-Meier method was used to draw survival curves,and the comparison between survival curves was conducted using Log-rank test.Results The incidence of coronary heart disease and the number of acute exacerbation in flutemeivir treatment group were lower than those in conventional treatment group(P<0.05).The results of multiple linear regression analysis showed that age,percentage of forced expiratory volume in one second to expected value(FEV_(1)%),arterial partial pressure of carbon dioxide(PaCO_(2)),COPD Assessment Test(CAT)score and treatment method were the influencing factors of the number of acute exacerbation in elderly COPD patients(P<0.05).There was no significant difference in cumulative all-cause mortality between the two groups(P>0.05).Conclusion Flutemeivir can effectively reduce the number of acute exacerbation in elderly patients with COPD,but it may not reduce the risk of death.